Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Treating cancer patients with oral medicine versus intravenous chemotherapy results in a 2/3 reduction in hospital time and a greater than 50% reduction in costly medication side effects.  
  • According to the Pharmaceutical Research and Manufacturers of America, researchers are currently working on 646 medicines for cancer. All are either in clinical trials or under FDA review. …  
  • Medicines in Development for Cancer  
  • FDA Cancer Approvals for Aug 2014 to July 2015
     
  • Since the war on cancer was declared in 1971, our arsenal has tripled. New drugs accounted for around 50-60% of the increase in six-year cancer survival rates since 1975.…